MedTrace Logo

Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19

NCT04715295 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-01-20

No results posted yet for this study

Summary

This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on D1 to D7) and Azithromycin (500 mg on D1 and 250mg on D2 to D5) as per national standard to treat ambulatory mild COVID-19 patients, with the aim to achieve early negativity of RT-PCR of SARS-CoV-2 from nasopharyngeal swab, and early clinical improvement and prevention of severe disease.

Conditions

Interventions

DRUG

Doxycycline Tablets

Doxycycline 200 mg daily for 7 days

DRUG

Rivaroxaban 15Mg Tab

Rivaroxaban 15 mg tablets daily from day 1 to day 10

COMBINATION_PRODUCT

Hydroxychloroquine and Azithromycin

Hydroxychloroquine 400mg daily from day 1 to day 5 in combination with Azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5

Sponsors & Collaborators

  • Yaounde Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Eugene Sobngwi · University of Yaounde 1

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2021-05-30
Completion
2021-09-05

Countries

  • Cameroon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04715295 on ClinicalTrials.gov